Advanced search
Publication Cover
Pediatric Hematology and Oncology Volume 38, 2021 - Issue 1
Submit an article Journal homepage
200
Views
5
CrossRef citations to date
0
Altmetric
Research Article

Initial in vivo testing of TPO-receptor agonist eltrombopag in osteosarcoma patient-derived xenograft models by the pediatric preclinical testing consortium

Grace Nevila Division of Pediatric Oncology, MD Anderson Children’s Cancer Hospital, The University of Texas MD Anderson Cancer Center, Houston, Texas, USAView further author information
,
Michael Rotha Division of Pediatric Oncology, MD Anderson Children’s Cancer Hospital, The University of Texas MD Anderson Cancer Center, Houston, Texas, USAView further author information
,
Jonathan Gilla Division of Pediatric Oncology, MD Anderson Children’s Cancer Hospital, The University of Texas MD Anderson Cancer Center, Houston, Texas, USAView further author information
,
Wendong Zhanga Division of Pediatric Oncology, MD Anderson Children’s Cancer Hospital, The University of Texas MD Anderson Cancer Center, Houston, Texas, USAView further author information
,
Beverly Teicherb National Cancer Institute, Bethesda, maryland, USAView further author information
,
Stephen W. Ericksonc RTI International, Research Triangle Park, North Carolina, USAView further author information
,
Gregory Gattoc RTI International, Research Triangle Park, North Carolina, USAView further author information
,
Malcom Smithb National Cancer Institute, Bethesda, maryland, USAView further author information
,
E. Anders Kolbd Division of Pediatric Hematology/Oncology, A.I. duPont Hospital for Children, Wilmington, Delaware, USAView further author information
&
Richard Gorlicka Division of Pediatric Oncology, MD Anderson Children’s Cancer Hospital, The University of Texas MD Anderson Cancer Center, Houston, Texas, USACorrespondence[email protected]
View further author information
 show all
Pages 8-13 | Received 21 Apr 2020, Accepted 10 Jul 2020, Published online: 17 Aug 2020

References

  • Luetke A, Meyers PA, Lewis I, Juergens H. Osteosarcoma treatment – where do we stand? A state of the art review. Cancer Treat Rev. 2014;40(4):523–532. doi:10.1016/j.ctrv.2013.11.006.
  • Harrison DJ, Geller DS, Gill JD, Lewis VO, Gorlick R. Current and future therapeutic approaches for osteosarcoma. Expert Rev Anticancer Ther. 2018;18(1):39–50. doi:10.1080/14737140.2018.1413939.
  • Meyers PA, Gorlick R. Osteosarcoma. Pediatr Clin North Am. 1997;44(4):973–989. doi:10.1016/s0031-3955(05)70540-x.
  • Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007;357(22):2237–2247. doi:10.1056/NEJMoa073275.
  • Young NS. Aplastic anemia. N Engl J Med. 2018;379(17):1643–1656. doi:10.1056/NEJMra1413485.
  • Winer ES, Safran H, Karaszewska B, et al. Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy: a randomized, placebo-controlled phase 2 study. Int J Hematol. 2017;106(6):765–776. doi:10.1007/s12185-017-2319-9.
  • Basciano PA, Bussel JB. Thrombopoietin-receptor agonists. Curr Opin Hematol. 2012;19(5):392–398.
  • Richardson D, Kalinowski D, Lau S, Jansson P, Lovejoy D. Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents. Biochim Biophys Acta. 2009;1790(7):702–717. doi:10.1016/j.bbagen.2008.04.003.
  • Roth M, Will B, Simkin G, et al. Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation. Blood. 2012;120(2):386–394. blood-2011-2012-399667. doi:10.1182/blood-2011-12-399667.
  • Will B, Kawahara M, Luciano JP, et al. Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. Blood. 2009;114(18):3899–3908. doi:10.1182/blood-2009-04-219493.
  • Rokita JL, Rathi KS, Cardenas MF, et al. Genomic profiling of childhood tumor patient-derived xenograft models to enable rational clinical trial design. Cell Rep. 2019;29(6):1675–1689. e1679. doi:10.1016/j.celrep.2019.09.071.
  • Houghton PJ, Morton CL, Tucker C, et al. The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer. 2007;49(7):928–940. doi:10.1002/pbc.21078.
  • Sun H, Tsai Y, Nowak I, Liesveld J, Chen Y. Eltrombopag, a thrombopoietin receptor agonist, enhances human umbilical cord blood hematopoietic stem/primitive progenitor cell expansion and promotes multi-lineage hematopoiesis. Stem Cell Res. 2012;9(2):77–86. doi:10.1016/j.scr.2012.05.001.
  • Mavroudi I, Pyrovolaki K, Pavlaki K, et al. Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome. Leuk Res. 2011;35(3):323–328. doi:10.1016/j.leukres.2010.06.029.
  • Olnes MJ, Scheinberg P, Calvo KR, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med. 2012;367(1):11–19. doi:10.1056/NEJMoa1200931.
  • Pahl PM, Horwitz LD. Cell permeable iron chelators as potential cancer chemotherapeutic agents. Cancer Invest. 2005;23(8):683–691. doi:10.1080/07357900500359976.
  • Vlachodimitropoulou E, Chen Y-L, Garbowski M, et al. Eltrombopag: a powerful chelator of cellular or extracellular iron (III) alone or combined with a second chelator. Blood. 2017;130(17):1923–1933. blood-2016-2010-740241. doi:10.1182/blood-2016-10-740241.
  • Dickinson M, Cherif H, Fenaux P, et al. Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia. Blood. 2018;132(25):2629–2638. doi:10.1182/blood-2018-06-855221.
  • Frey N, Jang JH, Szer J, et al. Eltrombopag treatment during induction chemotherapy for acute myeloid leukaemia: a randomised, double-blind, phase 2 study. Lancet Haematol. 2019;6(3):e122–e131. doi:10.1016/S2352-3026(18)30231-X.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.